A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy
Guo-Bin Ding
1, 2
,
Junqing Sun
1, 2
,
Peng Yang
1, 2
,
Bin-Chun Li
1
,
Ying Gao
3
,
Zhuoyu Li
1, 2, 3
Publication type: Journal Article
Publication date: 2017-12-15
scimago Q1
wos Q1
SJR: 0.968
CiteScore: 7.8
Impact factor: 4.5
ISSN: 15438384, 15438392
PubMed ID:
29207873
Drug Discovery
Pharmaceutical Science
Molecular Medicine
Abstract
Glucose-regulated protein of 78 kDa (GRP78) has become an attractive and novel target for tumor therapy. Design and construction of powerful delivery systems that could efficiently transport doxorubicin (DOX) to a tumor-cell nucleus remains a formidable challenge for improving the tumor therapeutic index and mitigating side effects to normal tissues. Herein, a novel doxorubicin prodrug (NDP) with GRP78 recognition and nucleus-targeting ability was synthesized by a facile chemical route. NDP exhibited an enhanced antiproliferative activity against colorectal cancer cells and could efficiently enter the cell nucleus. Furthermore, it is inspiring to note that NDP displayed a much stronger inhibitory efficacy against the growth of colorectal cancer xenografts in nude mice than free DOX and showed superior in vivo safety. Together, the work provides a novel GRP78 and nucleus-targeting strategy, and the NDP holds great promise to be used as a potent and safe chemotherapeutic agent.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Journal of Controlled Release
2 publications, 11.76%
|
|
|
Biomaterials Science
2 publications, 11.76%
|
|
|
Bioconjugate Chemistry
1 publication, 5.88%
|
|
|
Molecules
1 publication, 5.88%
|
|
|
3 Biotech
1 publication, 5.88%
|
|
|
Bioactive Materials
1 publication, 5.88%
|
|
|
Drug Discovery Today
1 publication, 5.88%
|
|
|
Biochemical Pharmacology
1 publication, 5.88%
|
|
|
Pharmacology and Therapeutics
1 publication, 5.88%
|
|
|
ACS applied materials & interfaces
1 publication, 5.88%
|
|
|
Journal of Translational Medicine
1 publication, 5.88%
|
|
|
Current Drug Delivery
1 publication, 5.88%
|
|
|
European Journal of Pharmacology
1 publication, 5.88%
|
|
|
Cell Biochemistry and Biophysics
1 publication, 5.88%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
Elsevier
7 publications, 41.18%
|
|
|
Springer Nature
3 publications, 17.65%
|
|
|
American Chemical Society (ACS)
2 publications, 11.76%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 11.76%
|
|
|
MDPI
1 publication, 5.88%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 5.88%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
17
Total citations:
17
Citations from 2024:
3
(17.64%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Ding G. et al. A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy // Molecular Pharmaceutics. 2017. Vol. 15. No. 1. pp. 238-246.
GOST all authors (up to 50)
Copy
Ding G., Sun J., Yang P., Li B., Gao Y., Li Z. A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy // Molecular Pharmaceutics. 2017. Vol. 15. No. 1. pp. 238-246.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1021/acs.molpharmaceut.7b00830
UR - https://doi.org/10.1021/acs.molpharmaceut.7b00830
TI - A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy
T2 - Molecular Pharmaceutics
AU - Ding, Guo-Bin
AU - Sun, Junqing
AU - Yang, Peng
AU - Li, Bin-Chun
AU - Gao, Ying
AU - Li, Zhuoyu
PY - 2017
DA - 2017/12/15
PB - American Chemical Society (ACS)
SP - 238-246
IS - 1
VL - 15
PMID - 29207873
SN - 1543-8384
SN - 1543-8392
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2017_Ding,
author = {Guo-Bin Ding and Junqing Sun and Peng Yang and Bin-Chun Li and Ying Gao and Zhuoyu Li},
title = {A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy},
journal = {Molecular Pharmaceutics},
year = {2017},
volume = {15},
publisher = {American Chemical Society (ACS)},
month = {dec},
url = {https://doi.org/10.1021/acs.molpharmaceut.7b00830},
number = {1},
pages = {238--246},
doi = {10.1021/acs.molpharmaceut.7b00830}
}
Cite this
MLA
Copy
Ding, Guo-Bin, et al. “A Novel Doxorubicin Prodrug with GRP78 Recognition and Nucleus-Targeting Ability for Safe and Effective Cancer Therapy.” Molecular Pharmaceutics, vol. 15, no. 1, Dec. 2017, pp. 238-246. https://doi.org/10.1021/acs.molpharmaceut.7b00830.
Profiles